Jaguar Health, Inc. (JAGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on November 11, 2022. The filing discloses the entry into a material definitive agreement and the unregistered sale of equity securities. The company is incorporated in Delaware and its common stock trades on the NASDAQ Capital Market under the symbol JAGX.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than standard operating financial results. Key metrics include:
- Gross Proceeds: $100 total.
- Securities Issued: 10 shares of Series F Preferred Stock.
- Price Per Share: $10.00 (Series F Original Issue Price).
- Investor: SynWorld Technologies Corporation.
- Liquidity: No established trading market exists for the Series F Preferred Stock, and the company does not expect one to develop.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or total debt as this is a transaction-specific report.
Material Changes and Transaction Terms
The primary material change is the issuance of Series F Preferred Stock to facilitate a potential reverse stock split. Key terms include:
- Voting Rights: The Series F shares have no general voting rights but possess 6,000,000,000 votes per share specifically for a proposed "Reverse Stock Split Amendment." This amendment would allow a reverse split of common stock at a ratio between 1-for-3 and 1-for-75.
- Liquidation Preference: The Series F stock ranks senior to common stock. In a liquidation event, holders are entitled to the Series F Liquidation Amount (equal to the original issue price) before common stockholders receive any payment.
- Dividends: Holders are not entitled to receive dividends.
- Redemption: The stock is subject to mandatory redemption no later than the 3rd business day following the stockholder vote on the Reverse Stock Split Amendment, at a price equal to the liquidation amount.
Outlook, Risks, and Management Commentary
Management plans to call a special meeting of stockholders to vote on the Reverse Stock Split Amendment. SynWorld has agreed to vote its Series F shares in the same proportion as the company's common stock is voted on this amendment. The filing notes that without an active trading market, the liquidity of the Series F Preferred Stock will be limited. The transaction was exempt from registration under Section 4(a)(2) and/or Rule 506(b) of Regulation D.
Investor Verification Checklist
- Verify the outcome of the Special Meeting regarding the Reverse Stock Split Amendment.
- Confirm the exact reverse stock split ratio selected by the Board of Directors (if approved), which must be between 1-for-3 and 1-for-75.
- Monitor the mandatory redemption of the Series F Preferred Stock following the stockholder vote.
- Review the full text of the Certificate of Designation (Exhibit 3.1) and Securities Purchase Agreement (Exhibit 10.1) for complete legal terms.